Cancer Immunotherapy Market Set to Soar Past USD 309.67 Billion by 2030 | Skyquest Technology

The global Cancer Immunotherapy market size is expected to reach USD 309.67 billion by 2030 and exhibit a CAGR of 9.6% in the forecast period (2023−2030), according to Skyquest's latest research report. The increasing prevalence of cancer, growing demand for targeted and personalized cancer treatments, advancements in immunotherapy research and technology, rising investments in cancer immunotherapy development, reimbursement support for immunotherapy treatments, favourable government initiatives and funding are fueling the market's growth.


Westford, USA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- According to SkyQuest's latest global research of the Cancer Immunotherapy market, increasing adoption of immune checkpoint inhibitors, development of combination therapies, the emergence of CAR-T cell therapy, expanding applications of immunotherapy across different cancer types, focus on biomarker research for patient selection, utilization of precision medicine approaches, advancements in immune-oncology research, exploration of novel immunotherapeutic targets, growing importance of immune monitoring and diagnostics, and integration of artificial intelligence and big data analytics in immunotherapy research and development are the trends that aid in the market's growth.

Browse in-depth TOC on "Cancer Immunotherapy Market"

  • Pages – 157       
  • Tables - 120
  • Figures - 77

Cancer immunotherapy is a cancer treatment that uses the body's immune system to fight cancer. It works by either stimulating the immune system to attack cancer cells or blocking their ability to evade the immune system.

Get a sample copy of this report:

https://www.skyquestt.com/sample-request/cancer-immunotherapy-market

Prominent Players in Cancer Immunotherapy Market

  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • Dendreon
  • Genentech
  • Gilead Sciences
  • ImmunoGen
  • Incyte
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
  • Sanofi
  • Seagen
  • Takeda Pharmaceutical Company
  • Tesaro

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/cancer-immunotherapy-market

Immune Checkpoint Inhibitors Demand to Grow Substantially in the Forecast Period

Immune checkpoint inhibitors dominated the global market owing to its high efficacy. It  also has shown efficacy across multiple cancer types, including melanoma, lung, bladder, and others. Their ability to target specific immune checkpoints, such as PD-1/PD-L1 and CTLA-4, makes them applicable to various cancers exhibiting checkpoint dysregulation.

Lung Cancer is the Leading Application Segment

In terms of application, lung cancer is the leading segment due to the growing prevalence of it. In addition, immunotherapy, particularly immune checkpoint inhibitors, has emerged as a standard treatment option for lung cancer. These drugs have demonstrated impressive results in improving overall survival and progression-free survival in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients.

North America is the leading Market Due to the Advanced Healthcare Infrastructure  

Region-wise, North America is one of the largest growing markets with a huge emphasis on the early adoption of immunotherapy. The United States has a well-established regulatory framework, with the U.S. Food and Drug Administration (FDA) playing a pivotal role in drug approvals. The FDA's support and expedited pathways for immunotherapies have facilitated faster market access and adoption of these treatments in North America.

A recent report thoroughly analyzes the major players operating within the Cancer Immunotherapy market. This comprehensive evaluation has considered several crucial factors, such as collaborations, mergers, innovative business policies, and strategies, providing invaluable insights into the key trends and breakthroughs in the market. Additionally, the report has carefully scrutinized the market share of the top segments and presented a detailed geographic analysis. Finally, the report has highlighted the major players in the industry and their ongoing endeavours to develop innovative solutions that cater to the ever-increasing demand for Cancer Immunotherapy.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/cancer-immunotherapy-market

Key Developments in Cancer Immunotherapy Market

  • In March 2023, AstraZeneca acquired Daiichi Sankyo's cancer immunotherapy business for $7.5 billion. This deal gave AstraZeneca a leading position in Japan's cancer immunotherapy market.

Key Questions Answered in Cancer Immunotherapy Market Report

  • What specific growth drivers will impact the market during the forecast period?
  • Can you list the top companies in the market and explain how they have achieved their positions of influence?
  • In what ways do regional trends and patterns differ within the global market, and how might these differences shape the market's future growth?

Related Reports in SkyQuest’s Library:

Global Pharmaceutical Manufacturing Market

Global Immune Health Supplements Market

Global Biopharmaceuticals Excipients Market

Global Acne Medication Market

Global Cough Syrup Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter